Grant: Operating Grant
McMaster University
$243,537.00
Extended Low-Molecular Weight Heparin VTE Prophylaxis in the Thoracic Surgical population, a randomized controlled pilot study
FY 2014-15
Summary
After any surgery, there is a risk of venous thromboembolism (VTE), or blood clots, that travel from one part of the body and get stopped in smaller veins, possibly causing disability or death after surgery. In the lung, this is called a Pulmonary Embolus (PE). In the major veins of the body, this is called Deep Vein Thrombosis (DVT). These clots are commonly prevented by the use of low-molecular-weight heparin, a blood thinner that prevents clotting. In most surgical specialties, like thoracic or vascular surgery, this treatment is used until patients are discharged from the hospital. However, in orthopaedic surgery, there is strong evidence that the use of longer term preventative treatment up to 35 days after discharge from the hospital helps to reduce VTE occurrences. In thoracic surgery, particularly surgery for lung cancer, there is a considerable risk of developing PE because of the surgical stress, the presence of cancer and the direct damage done to blood vessels in the lung during surgery. Since there is a high risk of VTE after these thoracic procedures, it is possible that longer use of clot-preventing medications may be as helpful in this patient group as it is in orthopaedic surgery. This hypothesis will be evaluated in a rigorous trial where patients undergoing lung cancer surgery will be asked to receive dalteparin, a commonly used blood thinner, either from surgery up to the time of discharge to home, or an extended treatment of up to 35 days after surgery. The number of PE and DVT events and other complications will be recorded until up to 90 days after surgery. This present request is for a small-scale trial that will help establish whether an extended therapy group will see a lower rate of clots in a later, larger trial. It is hoped that this extended therapy will help reduce the risk of post-surgical death and disability for patients undergoing lung cancer surgery while limiting the impact to resources in the Canadian health care system.
Department
Program
Operating Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
323687
Name
Shargall Yaron
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - C: Digestive, Endocrine and Excretory Systems
Projecttitle
Extended Low-Molecular Weight Heparin VTE Prophylaxis in the Thoracic Surgical population, a randomized controlled pilot study
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$243,537
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Anti-Coagulation; Dalteparin; Lung Cancer; Prospective; Thoracic Surgery; Venous Thromboembolism
Abstract
After any surgery, there is a risk of venous thromboembolism (VTE), or blood clots, that travel from one part of the body and get stopped in smaller veins, possibly causing disability or death after surgery. In the lung, this is called a Pulmonary Embolus (PE). In the major veins of the body, this is called Deep Vein Thrombosis (DVT). These clots are commonly prevented by the use of low-molecular-weight heparin, a blood thinner that prevents clotting. In most surgical specialties, like thoracic or vascular surgery, this treatment is used until patients are discharged from the hospital. However, in orthopaedic surgery, there is strong evidence that the use of longer term preventative treatment up to 35 days after discharge from the hospital helps to reduce VTE occurrences. In thoracic surgery, particularly surgery for lung cancer, there is a considerable risk of developing PE because of the surgical stress, the presence of cancer and the direct damage done to blood vessels in the lung during surgery. Since there is a high risk of VTE after these thoracic procedures, it is possible that longer use of clot-preventing medications may be as helpful in this patient group as it is in orthopaedic surgery. This hypothesis will be evaluated in a rigorous trial where patients undergoing lung cancer surgery will be asked to receive dalteparin, a commonly used blood thinner, either from surgery up to the time of discharge to home, or an extended treatment of up to 35 days after surgery. The number of PE and DVT events and other complications will be recorded until up to 90 days after surgery. This present request is for a small-scale trial that will help establish whether an extended therapy group will see a lower rate of clots in a later, larger trial. It is hoped that this extended therapy will help reduce the risk of post-surgical death and disability for patients undergoing lung cancer surgery while limiting the impact to resources in the Canadian health care system.
Competitiondate
201503
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shargall, Yaron
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $243,537~ $0~